<DOC>
	<DOCNO>NCT00025181</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Vaccines make person 's cancer cell may make body build immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness combine monoclonal antibody therapy vaccine therapy treat patient stage III stage IV melanoma remove surgery .</brief_summary>
	<brief_title>Monoclonal Antibody Vaccine Therapy Treating Patients With Stage III Stage IV Melanoma That Has Been Removed During Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety adverse event profile anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody combine tyrosinase:368-376 , gp100:209-217 , MART-1:26-35 peptide emulsify Montanide ISA-51 patient resect stage III IV melanoma . - Determine regimen cause antigen-specific T-cell activation patient . - Determine clearance profile regimen patient . - Assess development host immune response patient treat regimen . OUTLINE : This dose-escalation study anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( MDX-CTLA4 ) . Patients receive tyrosinase:368-376 , gp100:209-217 , MART-1:26-35 peptide emulsify Montanide ISA-51 subcutaneously follow MDX-CTLA4 IV 90 minute 0 , 1 , 2 , 3 , 4 , 5 , 8 , 11 month absence disease progression unacceptable toxicity . Cohorts least 6 patient receive escalate dos MDX-CTLA4 maximum tolerate dose determine . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter disease progression . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm completely resect stage III IV melanoma Mucosal ocular subtypes allow HLAA2 positive Positive stain tumor tissue antibody HMB45 gp100 , tyrosinase , and/or MART1 Failed ( ineligible refusal ) interferon alfa PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 60100 % Life expectancy : At least 12 month Hematopoietic : WBC least 2,500/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hematocrit least 30 % Hepatic : Bilirubin great upper limit normal ( ULN ) AST great 1.25 time ULN Hepatitis B surface antigen negative Hepatitis C antibody nonreactive Renal : Creatinine le 1.25 time ULN Immunologic : Antinuclear antibody ( ANA ) negative OR If ANA positive , must : Antithyroglobulin antibody negative Rheumatoid factor negative AntiLKM antibody negative Antiphospholipid antibody negative Antiislet cell antibody negative Antineutrophil cytoplasmic antibody negative HIV negative No autoimmune disease ( e.g. , uveitis autoimmune inflammatory eye disease ) No active infection No hypersensitivity tyrosinase:368376 , gp100:209217 , MART1:2635 , Montanide ISA51 Other : No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix No underlying medical condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody No prior tyrosinase , gp100 , MART1 peptide No prior antitumor vaccination No prior interleukin2 At least 4 week since prior immunotherapy melanoma Chemotherapy : At least 4 week since prior chemotherapy melanoma Endocrine therapy : At least 4 week since prior hormonal therapy melanoma At least 4 week since prior corticosteroid No concurrent systemic topical corticosteroid Radiotherapy : At least 4 week since prior radiotherapy melanoma Surgery : See Disease Characteristics Other : No prior cytotoxic therapy At least 4 week since prior therapy melanoma Concurrent analgesic allow stable dose least 2 week study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , small size</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>